Results 31 to 40 of about 6,917 (184)

Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)

Pleura and Peritoneum, 2023
There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes ...
Falla-Zuniga Luis Felipe, Sardi Armando, King Mary Caitlin, Lopez-Ramirez Felipe, Barakat Philipp, Nieroda Carol, Diaz-Montes Teresa, Gushchin Vadim   +7 more
doaj   +1 more source

A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma [PDF]

Revista do Colégio Brasileiro de Cirurgiões, 2017
ABSTRACT Cytoreductive surgery plus hypertermic intraperitoneal chemotherapy has emerged as a major comprehensive treatment of peritoneal malignancies and is currently the standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome as well as malignant peritoneal mesothelioma.
Batista, Thales Paulo, Sarmento, Bruno José Queiroz, Loureiro, Janina Ferreira, Petruzziello, Andrea, Lopes, Ademar, Santos, Cassio Cortez, Quadros, Cláudio de Almeida, Akaishi, Eduardo Hiroshi, Cordeiro, Eduardo Zanella, Coimbra, Felipe José Fernández, Laporte, Gustavo Andreazza, Castro, Leonaldson Santos, Batista, Ranyell Matheus Spencer Sobreira, Aguiar Júnior, Samuel, Costa Júnior, Wilson Luiz, Ferreira, Fábio Oliveira   +15 more
openaire   +4 more sources

Therapeutic approaches in patients with bone metastasis due to endometrial carcinoma – A systematic review

Journal of Bone Oncology, 2023
Background: Bone metastases (BM) are uncommon in endometrial carcinoma (EC), without information on the optimal oncologic management of patients with BM in EC. Here, we systematically review clinical characteristics, treatment approaches and prognosis in
Martin Heidinger, Elisa Simonnet, Li Mei Koh, Brigitte Frey Tirri, Marcus Vetter   +4 more
doaj   +1 more source

Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer [PDF]

, 2011
BACKGROUND: Ovarian cancer is the sixth most common cancer among women and the leading cause of death in women with gynaecological malignancies. Opinions differ regarding the role of ultra-radical (extensive) cytoreductive surgery in ovarian cancer ...
Ang, C, Bryant, A, Chan, KKL, Dickinson, HO, Naik, R   +4 more
core   +1 more source

83 Impact of introducing extensive surgical procedures to cytoreductive surgery (CRS) in advanced epithelial ovarian cancer (EOC) on rate of complete debulking (CD) and survival [PDF]

E-Poster discussions, 2019
Objectives To asses the impact of extensive procedures (Diaphragmatic resection, large and small bowel resection, complete peritonectomy, complete omentectomy, paraaortic lmph node dissection, splenectomy, resection of all visible disease) in CRS on the rate of CD, progression free (PFS), and overall survival (OS) in patients with advanced EOC ...
M Seoud, A El Housheimi, I Jaafar, K Hamed, R Abdallah, A Khalil, F Jamali   +6 more
openaire   +1 more source

Peritoneal carcinosis of ovarian origin [PDF]

, 2010
Epithelial ovarian cancer (EOC) is the second most common genital malignancy in women and is the most lethal gynecological malignancy, with an estimated five-year survival rate of 39%.
Fagotti, A, Fanfani, F, Gallotta, V, Naldini, A, ROMANO, Federico, Rossitto, C, Scambia, G., Vigliotta, M   +7 more
core   +2 more sources

Perioperative management of cytoreductive surgery and hyperthermic intraoperative thoraco-abdominal chemotherapy (HITAC) for pseudomyxoma peritonei

Indian Journal of Anaesthesia, 2019
Peritoneal carcinomatosis is intraperitoneal spread of gastrointestinal and gynaecological cancers. Cytoreductive surgeries and hyperthermic intraperitoneal chemotherapy offers survival benefits in these cases.
Sohan Lal Solanki, Jhanvi S Bajaj, Febin Rahman, Avanish P Saklani   +3 more
doaj   +1 more source

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena, Ceelen, Wim, Remaut, Katrien, Van Ramshorst, Gabrielle, Willaert, Wouter   +4 more
core   +1 more source

Peritoneal carcinomatosis [PDF]

, 2013
Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has been shown to significantly decrease overall survival in patients with liver
Ansaloni L, BAIOCCHI, Gian Luca, Catena F., Coccolini F, Ghermandi C, GHEZA, Federico, GIULINI, Stefano Maria, Iusco D, Lotti M, Melotti R, Virzì S   +10 more
core   +1 more source

Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)

Indian Journal of Anaesthesia, 2019
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for primary peritoneal malignancies or peritoneal spread of malignant neoplasm is being done at many centres worldwide.
Sohan Lal Solanki, Sudipta Mukherjee, Vandana Agarwal, Raghu S Thota, Kalpana Balakrishnan, Shagun Bhatia Shah, Neha Desai, Rakesh Garg, Reshma P Ambulkar, Nitin Madhukar Bhorkar, Viplab Patro, Snita Sinukumar, Meenakshi V Venketeswaran, Malini P Joshi, Rajesh Holalu Chikkalingegowda, Vijaya Gottumukkala, Pascal Owusu-Agyemang, Avanish P Saklani, Sanket Sharad Mehta, Ramakrishnan Ayloor Seshadri, John C Bell, Sushma Bhatnagar, Jigeeshu V Divatia   +22 more
doaj   +1 more source